AMPAR peptide assay and test kit
 
 
 
 
 
 
 
 
 
  • Description/features: 

    • The assessment of primary (often asymptomatic or subclinical) effect of impact or acute concussions.

  •  Intended to use: 

    • Selection of persons with concussion for advanced neuroimaging and further therapy if necessary;

    • Aid in making the decision to return to work, play, or duty.

  • GRACE Labs offers the product to

    • End-user (customer referred by physician)

    • Researchers 

Products Pipeline

 

In collaboration with Georgia Institute of Technology (GT, Atlanta, GA) the company is developing MEM device (GT’ IP) detecting biomarkers (GRACE Labs’ IP) to assess possible brain injury during perioperative period (surgery setting). The project: rapid point-of-care (POC) blood tests based on a mobile laboratory device platform that can detect multiple brain biomarkers for the assessment of concussions severity and its sequelae is designed in cooperation with European partners. The utilization of nanoparticles in the project will increase performance characteristics, speed up the detection time, and reduce the rate of unique reagents used for manufacturing. A mobile device employed to measure the one-step reaction will eliminate the requirements of laboratory conditions (turnaround time, blood withdrawal, processing, and storage).

 

A natural peptide inhibitor of AMPAR with moderate blocking power that could protect the brain from deterioration caused by mild TBI is in exploration. It was demonstrated that synthetic peptide Glyzargin significantly increases neuronal survival caused by neurotoxicity  reducing GluR1 peptide levels in plasma by 40–45% when injected 3 hours after the impact in animal model of concussion. Glyzargin didn’t alter cerebral blood flow or physiological parameters while down-regulated GluR1 antibody levels by 50% from day 3 after the impact.

Patents:

  • Immunosorbent blood tests for assessing paroxysmal cerebral discharges. August 16, 2006: EP1689288-A2

  • Immunosorbent tests for assessing paroxysmal cerebral discharges. May 26, 2005: WO/2005/046442

  • Nmdar biomarkers for diagnosis and treatment of traumatic brain injury and other disorders. June 19, 2008: WO/2008/073988

  • Immunosorbent blood tests for assessing paroxysmal cerebral discharges. April 25, 2007: CN200480039951

  • Nmdar biomarkers for diagnosis and treatment of traumatic brain injury and other disorders. October 29, 2013: US 8,569,448 B2

  • Immunosorbent for use in the diagnosis of neuropsychological  disorders, and use thereof. Japanese Patent 1998:2782695.

Publications:

  • Dambinova SA, Sowell RL, Maroon J. Gradual Return to Play: Potential role of neurotoxicity biomarkers in assessment of concussions severity. J Mol Biomar Diagn, 2013, S3:003.

  • Dambinova SA, Shikuev AV, Weissman JD, Mullins JD. AMPAR peptide values in blood of nonathletes and club sport athletes with concussions. Military Med, 2013, 178:285-290.

  • Dambinova SA, Hayes R, Wang K. Biomarkers for TBI. RSC Drug Discovery Series, RSC Publishing House, London, UK, 2012, 226 p.

  • Dambinova SA. Diagnostic Challenges in Traumatic Brain Injury. Blood Assay Development. IVD Technology, 2007, March (3).

  • Dambinova SA, Granstrem OK, Tourov A, Salluzzo R, Castello F, Izykenova GA. Monitoring of brain spiking activity and autoantibodies to N-terminus domain of GluR1 subunit of AMPA receptors in blood serum of rats with cobalt-induced  epilepsy. J. Neurochem. 1998; 71: 2088-2093.

  • Dambinova SA, Izykenova GA, Burov SV, Grigorenko EV, Gromov SA. The presence of autoantibodies to N-terminus domain of GluR1 subunit of AMPA receptor in the blood serum of patients with epilepsy. J.Neurol. Sci. 1997; 152: 93-97.

  • Dambinova SA, Gromova, L.G.  Autoantibodies against human brain AMPA/quisqualate receptor capable of determining persons with brain paroxysmal activity and epilepsy. In: “Neurochemistry”, eds. A.Teelken and J.Korf. New York: Plenum. 1997: 265-74

Technology & Products

AMPAR antibody assay and test kit
 
 
 
 
 
 
 
 
 
  • Description/features:

    • The risk assessment of post-traumatic epilepsy (PTE)

  • Intended to use:

    • Selection of persons with concussion for electroencephalography (EEG) and neurologist consultation;

    • Making decision to further treatment if necessary.

© 2014 by Grace labs. LLC. All Rights Reserved.

Grace laboratories, LLC.

 

2701 North Decatur Rd Decatur GA, 30033

Mon-Fri 10am-6pm

 

e-mail: info@gracelaboratories.com

Tel: (404) 576-8856

Grace Labs
  • Facebook Clean
  • Twitter Clean